NCT04633239 2026-03-18
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
56 trialsNCT06498648 2026-03-18
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06654037 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07209449 2026-03-18
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05940493 2026-03-13
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase 2 Recruiting
NCT07100106 2026-03-12
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Genentech, Inc.
Phase 1/2 Recruiting
NCT06065748 2026-03-09
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT05708235 2026-03-05
MiRaDoR
MedSIR
Phase 2 Recruiting
NCT06760637 2026-03-02
FourLight-3
Pfizer
Phase 3 Recruiting
NCT06179303 2026-02-27
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT06188520 2026-02-24
CYCAD-1
AstraZeneca
Phase 1/2 Recruiting
NCT02693535 2026-02-13
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT06678269 2026-02-12
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06366347 2026-02-11
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04923542 2026-02-06
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT05386108 2026-02-05
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06810544 2026-02-02
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05305924 2026-01-28
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT05696626 2026-01-26
ELAINEIII
Sermonix Pharmaceuticals Inc.
Phase 3 Recruiting
NCT04941274 2026-01-23
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT06835972 2026-01-15
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05501704 2026-01-07
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07002177 2026-01-07
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT06409390 2025-12-04
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06139107 2025-11-14
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Rutgers, The State University of New Jersey
Phase 1 Recruiting
NCT02977780 2025-11-10
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05608252 2025-10-29
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT07190443 2025-09-29
AURA
Japanese Foundation for Cancer Research
Phase 3 Recruiting
NCT04305834 2025-09-24
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
Phase 2 Recruiting
NCT05735080 2025-09-19
INX-315-01
Incyclix Bio
Phase 1/2 Recruiting
NCT05113537 2025-09-18
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT04486352 2025-09-04
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT06365788 2025-09-04
ABBICAR
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT03310879 2025-09-02
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT04040205 2025-07-20
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Medical College of Wisconsin
Phase 2 Recruiting
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT03675893 2025-06-15
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04614194 2025-06-02
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT05362760 2025-05-16
MINERVA
University of Ulm
Phase 4 Recruiting
NCT04523857 2025-04-04
ABBY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05095207 2025-04-02
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT06594679 2025-03-28
NICHOL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting